ESR1 and breast carcinoma: More importantly, we detected coexpression of GPR30 and ERα in approximately 40 % of the primary breast cancers, with GPR30 constituting a favorable factor for the outcome of patients, but an unfavorable indicator for patients receiving TAM [8, 29].